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ABSTRACT 26 
Objective: Ovarian cancers comprise several morphologically distinct tumour 27 
groups with widely different prognosis. We aimed to describe the worldwide 28 
distribution of ovarian cancer morphology and to understand what role this 29 
may play in international variation in survival. 30 
 31 
Methods: The CONCORD programme is the largest population-based study 32 
of global trends in cancer survival. Data on 681,759 women diagnosed during 33 
1995-2009 with cancer of the ovary, fallopian tube, peritoneum and 34 
retroperitonum in 51 countries were included. We categorised ovarian 35 
tumours into six morphological groups, and explored the worldwide 36 
distribution of morphology. 37 
 38 
Results: During 2005-2009, type II epithelial tumours were the most common. 39 
The proportion was much higher in Oceania (73.1%), North America (73.0%) 40 
and Europe (72.6%) than in Central and South America (65.7%) and Asia 41 
(56.1%). By contrast, type I epithelial tumours were more common in Asia 42 
(32.5%), compared with only 19.4% in North America. From 1995 to 2009, the 43 
proportion of type II epithelial tumours increased from 68.6% to 71.1%, while 44 
the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The 45 
proportions of germ cell tumours, sex cord-stromal tumours, other specific 46 
non-epithelial tumours and tumours of non-specific morphology all remained 47 
stable over time. 48 
 49 
Conclusions: The distribution of ovarian cancer morphology varies widely 50 
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worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are 51 
generally associated with higher survival than type II tumours, so the 52 
proportion of these tumours may influence survival estimates for all ovarian 53 
cancers combined. The distribution of morphological groups should be 54 
considered when comparing survival between countries and regions. 55 
 56 
Word count: 25057 
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Introduction 58 
Of all gynaecological malignancies, ovarian cancer causes the second highest 59 
number of deaths worldwide, accounting for over 151,000 deaths annually(1). 60 
Symptoms, such as persistent abdominal pain, bloating or decreased 61 
appetite, are vague(2). Most women present with advanced-stage disease(3) 62 
and five-year survival is around 30-40%(4). Ovarian cancer is not a single 63 
disease(2, 5), but includes several morphological subtypes that have widely 64 
different prognosis(6, 7).  65 
 66 
Ovarian cancer has been divided into epithelial and non-epithelial groups for 67 
many years, but recent work has enabled finer subdivision of epithelial ovarian 68 
cancers into different groups according to a combination of morphological and 69 
clinical characteristics(6-10). Type I epithelial tumours include low-grade 70 
serous, endometrioid, clear cell, mucinous and transitional cell (Brenner) 71 
carcinomas. They often present at an early stage, may arise from borderline 72 
ovarian tumours or endometriosis and typically have a good prognosis. Type II 73 
epithelial tumours comprise high-grade serous carcinoma, undifferentiated 74 
carcinomas and malignant mixed mesodermal tumours. They account for 75 
around 75% of epithelial ovarian cancers, typically present at an advanced 76 
stage and have a poor prognosis(6, 7, 9). Each morphological group has 77 
distinct molecular pathways that influence chemosensitivity, the pattern of 78 
metastasis and the probability of survival(9, 11). 79 
 80 
The pathogenesis of ovarian cancer is not fully understood. Recent evidence, 81 
particularly from prophylactic oophorectomies in women at a high risk of 82 
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ovarian cancer because of BRCA gene mutations, suggests that the most 83 
common subtype, high-grade serous carcinoma, originates either in the 84 
fallopian tube or on the surface of the ovary. Therefore, fallopian tube 85 
carcinoma has more recently been included in a broader definition of ovarian 86 
cancer(7). Primary peritoneal carcinoma is also managed in the same way as 87 
advanced-stage epithelial ovarian cancer(6, 12). 88 
 89 
International comparisons of cancer incidence, mortality and survival are 90 
crucial to inform and plan health policy and cancer control programmes. Low 91 
survival has been a stimulus for cancer plans and strategies in many 92 
countries, such as the United Kingdom and Denmark(3). Comparisons of lung 93 
cancer survival have routinely been divided into small-cell and non-small cell 94 
subtypes due to the different prognosis and behaviour of these tumours. 95 
Ovarian cancer is arguably an even more heterogeneous disease than lung 96 
cancer, and morphology should thus be considered in the interpretation of 97 
international variation in ovarian cancer survival. Type I epithelial tumours are 98 
generally associated with higher survival than type II tumours, so the 99 
proportion of type I epithelial tumours may influence survival estimates for all 100 
ovarian cancers combined. Differences in the distribution of morphology may 101 
thus contribute to international variations in survival from all ovarian cancers 102 
combined, in addition to international differences in stage at diagnosis and 103 
treatment. 104 
 105 
The CONCORD-2 study on the global surveillance of cancer survival has 106 
shown the extent to which ovarian cancer survival varies worldwide(4). 107 
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However, it remains unclear how much of the variation in ovarian cancer 108 
survival could be attributed to international variation in the morphological 109 
subtypes, in particular the distribution of type I and type II epithelial tumours. 110 
Using population-based data from the CONCORD-2 study, we have examined 111 
the international distribution of ovarian cancer morphology. Our aims were to 112 
describe the worldwide variation of ovarian cancer morphological groups, and 113 
then to discuss whether this variation may influence international comparisons 114 
of population-based cancer survival. 115 
 116 
Methods 117 
The CONCORD-2 study(4) collected information for over 779,000 adult 118 
women (aged 15-99 years) in 61 countries who were diagnosed during the 15-119 
year period 1995-2009 with a cancer of the ovary, fallopian tube, uterine 120 
ligaments and adnexa, other specific and unspecified female genital organs, 121 
peritoneum or retroperitoneum (International Classification of Diseases for 122 
Oncology, 3rd edition (ICD-O-3) topography codes C56.9, C57.0-C57.4, 123 
C57.7-C57.9, C48.0-C48.2)(13). The CONCORD-2 protocol, the ethical 124 
approvals and the quality control procedures have been described(4).  125 
 126 
We defined six morphological groups based on previous literature(14) and 127 
clinical advice [Table 1]. Clear cell, endometrioid, mucinous, squamous and 128 
transitional cell carcinomas were grouped as type I epithelial tumours, and 129 
serous carcinoma, mixed epithelial and stromal carcinoma and 130 
undifferentiated and other epithelial carcinoma were grouped as type II 131 
epithelial tumours.  132 
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 133 
Ovarian cystadenomas were reclassified in ICD-O-3 from invasive (behaviour 134 
code of 3) to borderline (behaviour code of 0 or 1), but some registries coded 135 
tumours of borderline behaviour as invasive despite the changes from ICD-O-136 
2 to ICD-O-3. Borderline tumours were excluded from the analysis of the 137 
distribution. Morphology codes for haematological malignancies were also 138 
excluded from analysis.  139 
 140 
Data were available for 793,098 women for analysis [supplementary Figure 1]. 141 
Women diagnosed with borderline tumours, haematological malignancies or 142 
whose records included invalid ICD-O-3 codes (codes not included in either 143 
ICD-O-2 or ICD-O-3) were excluded (n=13,073). Of the remaining 780,025 144 
women, 90.6% (706,807) had tumours that were coded by the registry as 145 
having been morphologically verified, while 7.5% (58,682) were coded as not 146 
morphologically verified and 1.9% (14,536) were coded as unknown whether 147 
morphologically verified or not. For tumours coded as morphologically verified, 148 
705,997 (99.9%) had a valid ICD-O-3 morphology code, but no morphology 149 
code was available for 810 (0.1%), and these tumours were excluded. 150 
Tumours coded as not morphologically verified were primarily tumours of 151 
unknown morphology (30,287, 51.6% of non-morphologically verified 152 
tumours); these tumours were excluded. We excluded a further 18,200 non-153 
morphologically verified tumours with non-specific morphology. We included 154 
the remaining 10,195 tumours that had been coded as not having been 155 
morphologically verified, because a specific ICD-O-3 morphology code was 156 
nevertheless available, implying that morphological verification had in fact 157 
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been performed. Tumours for which it was unknown whether morphological 158 
verification had been performed or not were evenly distributed across specific 159 
(n=5,017), non-specific (n=4,798) and unknown morphology (n=4,721). Of 160 
these tumours, we excluded non-specific and unknown tumours. We included 161 
the remaining 5,017 tumours coded as unknown whether morphologically 162 
verified, because a specific morphology was also recorded, again implying 163 
that morphological verification had been completed.  164 
 165 
In total, 721,209 women (98.3% with specific ICD-O-3 morphology codes and 166 
1.7% with non-specific codes) were available for analysis after the first round 167 
of exclusions.  168 
 169 
We examined the distribution of ovarian cancer morphology for all countries in 170 
any calendar period (1995-1999, 2000-2004 and 2005-2009) for which data 171 
were available for at least 100 women. Registries from which the survival 172 
estimates in the main CONCORD-2 analysis were considered less reliable(4) 173 
were also excluded, because the results from this analysis will be used to 174 
inform the results of survival analyses of ovarian cancer. Survival estimates 175 
were flagged as less reliable if a higher than usual proportion of patients was 176 
excluded from analyses because the cancer was registered only through a 177 
death certificate, or the date of last vital status was not known. The focus of 178 
this analysis was the distribution of specific morphological groups, so women 179 
diagnosed in Sweden had to be excluded, because 97.5% of tumours were 180 
coded by the registry as undifferentiated or other epithelial carcinoma or as 181 
non-specific morphology (ICD-O-3 codes 8000-8004). After all exclusions, 182 
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681,759 women (86.0% of the total number for whose data were available for 183 
analysis) were included in the analysis of the morphological distribution 184 
(192,080 in 1995-1999; 240,397 in 2000-2004; 249,282 in 2005-2009) 185 
[supplementary Table 1]. 186 
 187 
Results  188 
Type II epithelial tumours were the most common morphology worldwide 189 
(476,461; 69.9%), followed by type I epithelial (152,874; 22.4%) [Figure 1]. 190 
Germ cell, sex cord-stromal, other specific non-epithelial and non-specific 191 
tumours were all rare and they only comprised 8% of tumours worldwide; the 192 
distribution of these groups remained relatively stable over the 15-year period 193 
1995 to 2009. The proportion of type II epithelial tumours increased slightly 194 
from 68.6% to 71.1% from 1995 to 2009, and there was a corresponding 195 
decrease in type I epithelial tumours (from 23.8% to 21.2%: supplementary 196 
Table 1).  197 
During 2005-2009, type II epithelial was the most common group in all 198 
continents, although the proportion was much higher in Oceania (73.1%), 199 
North America (73.0%) and Europe (72.6%) than in Central and South 200 
America (65.7%) and Asia (56.1%) [Table 2]. The range at the national level, 201 
however, was much wider. The highest proportion of type II tumours was in 202 
Latvia (78.9%), with the lowest proportion in Thailand (40.4%) [supplementary 203 
Table 4]. There was little between-country variation in the proportion of type II 204 
tumours in Central and South America, North America and Oceania. However, 205 
the proportion varied widely in Asia, where the proportion of type II tumours 206 
was lower than that of type I epithelial tumours in Hong Kong and Thailand 207 
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[Figure 3]. There was also variation in the proportion of type II tumours in 208 
Europe, where they accounted for over 70% of tumours in 15 countries, 60% 209 
in 11 countries and only 50.2% in Russia [supplementary Table 4]. The 210 
distribution of type II epithelial subtypes (serous, undifferentiated and other 211 
epithelial and mixed epithelial and stromal carcinoma) also varied by country, 212 
continent and calendar period [supplementary Table 2, supplementary Table 3 213 
and supplementary Table 5].  214 
 215 
Type I epithelial tumours were the second most common group for all 216 
continents during 2005-2009, but the range was wide. The highest proportion 217 
was seen in Asia (32.5%), while North America showed the lowest proportion 218 
(19.4%) [Table 2]. The proportion was similar in all countries in Central and 219 
South America, North America and Oceania [supplementary Table 4]. In 220 
Europe, however, there was wider variation, the proportion ranging from 221 
11.3% in Latvia to 28.7% in Finland [supplementary Table 4]. The variation 222 
was even wider for countries in Asia, with the lowest proportion in Israel 223 
(12.8%) and the highest in Hong Kong (51.7%) [Figure 3]. The distribution of 224 
specific type I epithelial subtypes (clear cell, endometrioid, mucinous, 225 
squamous and transitional cell (Brenner)) also varied over time and differed 226 
by country and continent [supplementary Table 2, supplementary Table 3 and 227 
supplementary Table 5].  228 
 229 
Germ cell tumours were uncommon everywhere; the proportion in Asia (4.2%) 230 
was the highest in any continent, over three times the proportion seen in 231 
Europe (1.3%) [Table 2]. The proportion was similar for all countries in Europe 232 
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(1.3%), North America (2.0%) and Oceania (2.5%). However, there was wide 233 
variation between countries in Central and South America and Asia. In Central 234 
and South America, the lowest proportion (1.6%) was seen in Cuba, and the 235 
highest (7.8%) in Ecuador [supplementary Table 4]. Among Asian countries, 236 
the variation was wider, with the lowest proportion in Cyprus (0.9%), and the 237 
highest in Jordan (8.1%) [Figure 3].  238 
 239 
Sex cord-stromal tumours were even more uncommon than germ cell 240 
tumours. The proportion also varied widely between countries in Asia, Central 241 
and South America and Europe. The proportion was similar for all countries in 242 
North America (1.5%) and Oceania (0.9%) [Table 2, supplementary Table 4]. 243 
The widest between-country variation was seen in Europe, with only 0.3% of 244 
tumours diagnosed as sex cord-stromal in Denmark, but 11.4% in Russia 245 
[supplementary Table 4]. In Central and South America, the proportion ranged 246 
from 1.6% in Brazil and Puerto Rico to 4.5% in Cuba. The lowest proportion in 247 
Asia was in Israel (0.6%), while the highest proportion was in Jordan (4.7%) 248 
[Figure 3].  249 
 250 
The highest proportion of other specific non-epithelial tumours (3.4%) was in 251 
Central and South America. The proportion was generally less than 5% in all 252 
countries, and between-country variation within each continent was small. The 253 
widest variation in the proportions was seen in Asia (0.5% in Indonesia and 254 
5.8% in Cyprus) and Europe (0.6% in Croatia and 5.9% in Iceland) 255 
[supplementary Table 4]. 256 
 257 
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Non-specific tumours generally accounted for 3% or less of ovarian tumours in 258 
all countries. The highest proportion was recorded in Russia (17.7%), much 259 
higher than the next highest proportion (Malta, 6.3%). The lowest proportions 260 
of non-specific tumours were seen in the Netherlands and Slovenia (0.1%) 261 
[supplementary Table 4].  262 
 263 
Discussion 264 
This is the largest study of the distribution of ovarian cancer morphology. It is 265 
based on individual patient records from 218 population-based cancer 266 
registries in 51 countries. Data were available for 681,759 women, including 267 
249,282 diagnosed between 2005 and 2009. Type II epithelial tumours were 268 
the most common morphological group in each continent, but the distribution 269 
of morphological groups varied greatly worldwide. The distribution was similar 270 
in Europe, North America and Oceania, while there was a much higher 271 
proportion of type I epithelial tumours seen in Asia and Central and South 272 
America.  273 
 274 
Previous studies of the morphological subtypes of ovarian cancer have 275 
focused on epithelial tumours, and they have generally been limited to a small 276 
number of countries. One meta-analysis included data for 98,099 women from 277 
41 studies published between 1992 and 2012, only 12 of which used data 278 
from population-based registries(15). The results were similar to those found 279 
in this study, with type II epithelial tumours more common than type I epithelial 280 
tumours. The distribution of subtypes between countries included in the meta-281 
analysis was heterogeneous.  282 
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 283 
Some of the variations in the distribution of ovarian cancer morphology may 284 
be explained by ethnicity. A higher proportion of type II epithelial tumours 285 
diagnosed between 2005 and 2009 was reported in Israel (77.8%) than in 286 
most other countries. This may be attributable to the fact that a high 287 
percentage of the population in Israel is of Jewish ancestry, in whom BRCA1 288 
and BRCA2 gene mutations are more common than in other populations. 289 
Serous tumours, which are classified as type II epithelial, are the most 290 
common morphological subtype among women with BRCA1 and BRCA2 291 
mutations(16).  292 
 293 
The proportions of type I and type II epithelial tumours were markedly different 294 
between the US and Japan. In Japan, 41.3% of tumours were type I epithelial 295 
and 47.5% were type II epithelial, compared to 19.0% and 73.2% in the US 296 
[supplementary Table 4]. The lower proportion of serous tumours in Japan 297 
and other East Asian countries is due in part to the higher proportion of clear 298 
cell cancers [supplementary Table 5]. These differences are most probably 299 
due to the higher incidence of endometriosis, a potential pre-cursor of clear 300 
cell and endometrioid tumours(17), in East Asian women(18).  301 
 302 
The proportion of mucinous tumours varied, ranging from over 10% in most 303 
Asian countries to 5-6% in most North American, European and Oceanian 304 
countries. The higher proportion in Japan is not clearly explained. Many 305 
tumours classified as mucinous may in fact be metastatic to the ovary from 306 
the gastrointestinal tract, including the stomach, which has a high incidence in 307 
Asia(19, 20). The reduction in the worldwide proportion of mucinous ovarian 308 
 14 
cancer from 9.2% to 6.8% between 1995-1999 and 2005-2009 309 
[supplementary Table 5] may be partially attributable to more accurate 310 
immunohistochemical and imaging assessment, which allows for the 311 
exclusion of primary mucinous tumours from a different primary site, 312 
particularly those of the gastrointestinal tract. It can otherwise be difficult to 313 
differentiate a true primary mucinous ovarian cancer from mucinous tumours 314 
that are metastatic to the ovary(21). 315 
 316 
Germ cell and sex cord-stromal tumours of the ovary should be considered 317 
separately in survival analysis, because they typically have higher survival 318 
than epithelial ovarian cancers. The proportion of germ cell tumours was less 319 
than 3% in most countries, but in some Asian and Central and South 320 
American countries, the proportions were much higher (5-8%). These 321 
differences are important, because the incidence of germ cell tumours is 322 
highest among young women and survival is usually very high, even with the 323 
tumour is diagnosed at an advanced stage, if optimal treatment is 324 
achievable(22). The higher proportion of germ cell tumours in Asia and 325 
Central and South America may therefore be due to the younger age profile of 326 
populations in these regions. The proportion of sex cord-stromal tumours was 327 
less than 2% in most countries, but much higher in some European countries. 328 
These differences are also important in the comparison of survival from 329 
ovarian cancers combined, because survival is much higher for sex cord-330 
stromal tumours than for epithelial ovarian cancers(23). 331 
 332 
Variation in the distribution of morphological groups of ovarian cancer may 333 
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impact international comparisons of survival from all ovarian cancers 334 
combined if countries with more favourable morphological distributions, where 335 
more tumours are classified as type I epithelial, germ cell or sex cord-stromal, 336 
are compared to survival in countries with higher proportions of type II 337 
epithelial tumours. In the main CONCORD-2 analysis(4), age-standardised 5-338 
year survival from all ovarian tumours combined was higher in some East 339 
Asian countries than in Europe, North America and Oceania. In Hong Kong, 5-340 
year survival was 52.9% for women diagnosed from 2005 to 2009, much 341 
higher than the highest level of survival in Europe (Finland: 44.9%), North 342 
America (US: 40.9%) and Oceania (Australia: 37.5%)(4). The proportion of 343 
type I epithelial tumours in Hong Kong (51.7%) was the highest among the 51 344 
countries, and Hong Kong was one of only two countries where type I 345 
epithelial tumours were more common than type II epithelial tumours. Thus, 346 
the higher survival for all ovarian cancers combined in Hong Kong may be 347 
partially explained by the more favourable distribution of morphology. A 348 
favourable distribution was also seen in Ecuador, with one of the highest 349 
proportions of germ cell tumours (7.8%), and age-standardised 5-year survival 350 
was 47.0% for all tumours combined(4). 351 
 352 
For many areas of the world, data from population-based cancer registries are 353 
still insufficient to allow meaningful comparisons of ovarian cancer 354 
morphology. Lack of accurate cancer registration in many areas, and the high 355 
proportion of non-specific morphology in many countries, still limits worldwide 356 
comparison of survival by morphology.  357 
 358 
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During 2005-2009, the highest proportion of tumours of non-specific 359 
morphology was seen in Russia (17.7%), which may explain the low 360 
proportion of type II epithelial tumours in the country, because many non-361 
specific tumours will be diagnosed at an advanced stage [supplementary 362 
Table 4]. In order to classify a tumour as a specific subtype, such as serous or 363 
endometrioid, a tissue biopsy or surgical resection is required; thus, 364 
morphology may not be correctly classified into a specific subtype if the 365 
disease is diagnosed at an advanced stage. In Central and South America, 366 
the largest registry (Puerto Rico) provided data only for 684 women, of which 367 
24.3% were recorded as having been diagnosed with undifferentiated or other 368 
epithelial carcinoma. The accuracy of morphology data is also reliant upon 369 
data transmission to the cancer registries and recording of morphology codes, 370 
so the distribution of subtypes may be affected by registry procedures and the 371 
classifications in use. For example, in Sweden, only 324 of 12,969 (2.5%) 372 
women with ovarian cancer were reported as being diagnosed with a specific 373 
morphology, compared with 6,311 of 7,322 women (86.2%) in Finland. 374 
Previous reports on ovarian cancer in Sweden showed over 98% specific 375 
morphology codes(24). Additionally, the distribution for Hong Kong included 376 
only epithelial tumours, because other ovarian cancer subtypes were not 377 
submitted. While Sweden was excluded from these analyses, Hong Kong was 378 
included because comparison of the most common subtypes, type I and type 379 
II epithelial, was still achievable.  380 
 381 
Variation between pathologists in the classification of ovarian tumours into 382 
specific histological subtypes may affect the distribution of subtypes within a 383 
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country, and thus, comparisons of the distributions of subtypes between 384 
countries. Various studies conducted from 1984 to 1994 of the reproducibility 385 
of the World Health Organization’s 1973 histological classification of ovarian 386 
tumours(25) showed only moderate levels of reproducibility(26). The WHO 387 
classification for ovarian tumours was updated in 1999(27), 2003(28) and 388 
2014(2). Because tumours diagnosed from 1995 to 2009 were included in the 389 
analysis, pathologists could have used either the 1973, 1999 or 2003 criteria 390 
to assign a histological subtype to a tumour included in the study. The 391 
definitions of the various histological subtypes do not change drastically over 392 
time from 1973 to 2003, so the edition used by the pathologist is not 393 
necessarily relevant. However, the definitions of the subtypes are general and 394 
the 2003 criteria did not include changes or criteria that could improve 395 
reproducibility; thus, observer variation remains an issue(26).  396 
Studies of immunohistochemical biomarkers and molecular genetic features 397 
for certain histological subtypes may allow for more reproducible diagnoses. 398 
TP53 mutations are found in 80% of women diagnosed with high-grade 399 
serous carcinoma, while KRAS, BRAF and ERBB2 mutations are more 400 
common in women with low-grade serous carcinoma. Mutations of CTNNB1, 401 
PTEN, PIK3CA are common in endometrioid tumours and KRAS mutations 402 
can be found in 50% of mucinous tumours. For clear cell carcinoma, 403 
mutations or ARID1A and PIK3CA are common(2, 6, 7, 9). With this 404 
knowledge and the updated WHO classification of 2014, reproducibility of the 405 
histological typing of ovarian cancers should improve.   406 
 407 
In order to classify serous tumours appropriately into morphological groups, 408 
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knowledge of the tumour grade is important. However, data on tumour grade 409 
are not routinely collected by cancer registries. For ovarian cancer, most 410 
serous carcinomas are high-grade, and will have been correctly classified in 411 
our analysis as type II epithelial, but a small proportion are low-grade, and 412 
should have been classified as type I epithelial(6, 7, 9, 10, 29, 30). Because 413 
the proportion of low-grade serous tumours is small(2), the effect of any 414 
misclassification on the distribution of morphology is expected to be minimal. 415 
The distinction between high-grade and low-grade serous carcinoma is 416 
important, because they have a distinct pathogenesis and are thought to be 417 
different diseases(6, 7). Low-grade serous carcinoma is more common in 418 
younger women, and is thought to arise from borderline serous tumours. In 419 
contrast, high-grade serous carcinoma is more common in older women, is 420 
thought to arise from tubal disease and typically exhibits p53 mutation(6, 7, 421 
31). Similarly, endometrioid tumours are classified as either low- or high-422 
grade, and classification into type I or type II epithelial has previously 423 
depended on tumour grade(7). Most endometrioid ovarian tumours will be 424 
low-grade(2), and some pathologists have argued that high-grade 425 
endometrioid tumours may not exist(7, 10). Distinguishing between high-grade 426 
endometrioid and high-grade serous tumours is difficult, and when distinction 427 
between endometrioid and serous tumours is unclear, most high-grade 428 
tumours may be classified as high-grade serous, because this subtype is 429 
more common than high-grade endometrioid(7, 10). Following an update in 430 
2016 of the original definitions of type I and type II epithelial tumours, all 431 
endometrioid tumours would now be categorised as type I, regardless of 432 
tumour grade(6). Future analyses of ovarian cancer survival should, if 433 
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possible, incorporate a distinction between high- and low-grade serous 434 
carcinoma, to reflect the current understanding of ovarian cancer 435 
pathogenesis and behaviour, and to classify serous carcinomas appropriately 436 
into type I and type II epithelial tumours.  437 
 438 
Carcinoma, NOS (ICD-O-3 morphology code 8010), large cell carcinoma, 439 
NOS (8012) and adenocarcinoma, NOS (8140) were categorised as 440 
undifferentiated and other epithelial tumours and grouped broadly as type II 441 
epithelial. There may also be some misclassification of these tumours, 442 
because these morphology codes are not specific codes, so classification into 443 
type I or type II is difficult. However, carcinoma (NOS), large cell carcinoma 444 
(NOS) and adenocarcinoma (NOS) are treated clinically as if they were high-445 
grade serous carcinomas, which are classified as type II. Therefore, we 446 
decided to categorise these tumours as type II epithelial. They comprise 447 
20.9% of tumours included in the analysis.  448 
 449 
Only morphologically verified tumours, or those with specific morphologies 450 
that implied morphological verification, were included in the analysis. This 451 
restriction may affect the distribution of morphological subtypes, because the 452 
morphology of advanced-stage tumours that are not fully investigated may be 453 
coded as non-specific or unknown. If more advanced-stage tumours are not 454 
morphologically verified and therefore excluded from analysis, the distribution 455 
of morphological groups may appear more favourable than it actually is.  456 
 457 
This worldwide study of ovarian cancer morphology has identified striking 458 
variations in morphological distribution, using data from population-based 459 
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cancer registries in 51 countries. The two main morphological groups of 460 
ovarian cancer have different prognosis, primarily due to differences in the 461 
distribution of stage, sensitivity to chemotherapy and response to surgical 462 
resection. International comparisons of ovarian cancer survival should take 463 
morphology into account, to help identify whether the distribution of 464 
morphological type contributes to international differences in ovarian cancer 465 
survival, which is typically reported for all morphological subtypes combined. 466 
To understand further the impact on survival, we are examining international 467 
differences in ovarian cancer survival by morphological group. Registration of 468 
both the morphology and the grade of ovarian cancers is important to help 469 
categorise these tumours more accurately into morphological groups, 470 
especially type I and type II epithelial. Increased support for the development 471 
of high-quality population-based cancer registries in low-income countries will 472 
also help improve international comparisons of ovarian cancer survival.  473 
Word count: 3801474 
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CONCORD Working Group 475 
Africa—Algeria: S Bouzbid (Registre du Cancer d'Annaba); M Hamdi-Chérif*, Z Zaidi 476 
(Registre du Cancer de Sétif); Gambia: E Bah, R Swaminathan (National Cancer 477 
Registry); Lesotho: SH Nortje, DC Stefan (Children’s Haematology Oncology 478 
Clinics - Lesotho); Libya: MM El Mistiri (Benghazi Cancer Registry); Mali: S Bayo, 479 
B Malle (Kankou Moussa University); Mauritius: SS Manraj, R Sewpaul-Sungkur 480 
(Mauritius Cancer Registry); Nigeria: A Fabowale, OJ Ogunbiyi* (Ibadan Cancer 481 
Registry); South Africa: D Bradshaw, NIM Somdyala (Eastern Cape Province 482 
Cancer Registry); Sudan: M Abdel-Rahman (University of Khartoum); Tunisia: L 483 
Jaidane, M Mokni (Registre du Cancer du Centre Tunisien). 484 
America (Central and South)—Argentina: I Kumcher, F Moreno (National Childhood 485 
Cancer Registry – National Cancer Institute); MS González, EA Laura (Registro 486 
Regional de Tumores del Sur de la Provincia de Buenos Aires); SB Espinola, GH 487 
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List of tables 786 
Table 1. Ovarian cancer morphological groups and subtypesa 787 
a No information on grade was available, therefore all endometrioid tumours were 788 
classified as type I epithelial. 789 
b No information on grade was available, therefore all serous tumours were classified 790 
as type II epithelial 791 
c Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) 792 
were excluded from the analysis of distribution of morphological subtypes (see text). 793 
 794 
Table 2. Distribution of morphological groups by continent and calendar period of 795 
diagnosisa 796 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) 797 
were excluded from the analysis of distribution of morphological subtypes (see text).  798 
b No information on grade was available, therefore all endometrioid tumours were 799 
classified as type I epithelial.  800 
c No information on grade was available, therefore all serous tumours were classified 801 
as type II epithelial.  802 
d Morphologically verified tumours with ICD-O-3 morphology codes 8000-8004. Only 803 
countries with at least 100 women in any given time period were included. All 804 
tumours with a specific ICD-O-3 morphology code were included. 805 
 806 
Supplementary Table 1. Distribution of ovarian cancer by morphological group and 807 
calendar period of diagnosisa  808 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) 809 
were excluded from the analysis of distribution of morphological subtypes (see text).  810 
b No information on grade was available, therefore all endometrioid tumours were 811 
classified as type I epithelial.  812 
c No information on grade was available, therefore all serous tumours were classified 813 
as type II epithelial.  814 
d Morphologically verified tumours with ICD-O-3 morphology codes 8000-8004. Only 815 
countries with at least 100 women in any given time period were included. All 816 
tumours with a specific ICD-O-3 morphology code were included.  817 
 818 
Supplementary Table 2. Distribution of type I and type II epithelial subtypes by 819 
calendar period of diagnosisa  820 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) 821 
were excluded from the analysis of distribution of morphological subtypes (see text).  822 
b No information on grade was available, therefore all endometrioid tumours were 823 
classified as type I epithelial.  824 
c No information on grade was available, therefore all serous tumours were classified 825 
as type II epithelial.  826 
d Morphologically verified tumours with ICD-O-3 morphology codes 8000-8004. Only 827 
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countries with at least 100 women in any given time period were included. All 828 
tumours with a specific ICD-O-3 morphology code were included.  829 
 830 
Supplementary Table 3. Distribution of type I and type II epithelial subtypes by 831 
continent calendar period of diagnosisa  832 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) 833 
were excluded from the analysis of distribution of morphological subtypes (see text).  834 
b No information on grade was available, therefore all endometrioid tumours were 835 
classified as type I epithelial.  836 
c No information on grade was available, therefore all serous tumours were classified 837 
as type II epithelial.  838 
d Morphologically verified tumours with ICD-O-3 morphology codes 8000-8004. Only 839 
countries with at least 100 women in any given time period were included. All 840 
tumours with a specific ICD-O-3 morphology code were included.  841 
 842 
Supplementary Table 4. Distribution of morphological groups by country and 843 
calendar period of diagnosisa  844 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) 845 
were excluded from the analysis of distribution of morphological subtypes (see text).  846 
b No information on grade was available, therefore all endometrioid tumours were 847 
classified as type I epithelial.  848 
c No information on grade was available, therefore all serous tumours were classified 849 
as type II epithelial.  850 
d Morphologically verified tumours with ICD-O-3 morphology codes 8000-8004. Only 851 
countries with at least 100 women in any given time period were included. All 852 
tumours with a specific ICD-O-3 morphology code were included.  853 
 854 
Supplementary Table 5. Distribution of type I and type II epithelial subtypes by 855 
country and calendar period of diagnosisa  856 
a Borderline tumours (ICD-O-3 codes: 8442, 8444, 8451, 8462, 8463, 8472, 8473) 857 
were excluded from the analysis of distribution of morphological subtypes (see text).  858 
b No information on grade was available, therefore all endometrioid tumours were 859 
classified as type I epithelial.  860 
c No information on grade was available, therefore all serous tumours were classified 861 
as type II epithelial.  862 
d Morphologically verified tumours with ICD-O-3 morphology codes 8000-8004. Only 863 
countries with at least 100 women in any given time period were included. All 864 
tumours with a specific ICD-O-3 morphology code were included.   865 
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List of figures 866 
Figure 1. Worldwide distribution of ovarian cancera morphology (%): 51 countries, 867 
1995-2009 868 
a Malignancies of the ovary (ICD-O-3 C56.9), fallopian tube, uterine ligaments and 869 
adnexa, and other and unspecified female genital organs (C57.0-C57.4, C57.7-870 
C57.9), and peritoneum and retroperitoneum (C48.0-C48.2). Endometrioid tumours 871 
are classified as type I epithelial (see text).  872 
Figure 2. Morphological groups of ovarian cancera: distribution by continent, 2005-873 
09 874 
a Malignancies of the ovary (ICD-O-3 C56.9), fallopian tube, uterine ligaments and 875 
adnexa, and other and unspecified female genital organs (C57.0-C57.4, C57.7-876 
C57.9), and peritoneum and retroperitoneum (C48.0-C48.2). Endometrioid tumours 877 
are classified as type I epithelial (see text).  878 
Figure 3. Morphological groups of ovarian cancera by country (Asia), 2005-09 879 
a Malignancies of the ovary (ICD-O-3 C56.9), fallopian tube, uterine ligaments and 880 
adnexa, and other and unspecified female genital organs (C57.0-C57.4, C57.7-881 
C57.9), and peritoneum and retroperitoneum (C48.0-C48.2). Endometrioid tumours 882 
are classified as type I epithelial (see text). *Data with 100% coverage of the national 883 
population. 884 
 885 
Supplementary Figure 1. Flow chart of data exclusions 886 
 887 
Supplementary Figure 2. Morphological groups by ovarian cancera by country 888 
(Central and South America), 2005-09 889 
a Malignancies of the ovary (ICD-O-3 C56.9), fallopian tube, uterine ligaments and 890 
adnexa, and other and unspecified female genital organs (C57.0-C57.4, C57.7-891 
C57.9), and peritoneum and retroperitoneum (C48.0-C48.2). Endometrioid tumours 892 
are classified as type I epithelial (see text). *Data with 100% coverage of the national 893 
population. 894 
 895 
Supplementary Figure 3. Morphological groups of ovarian cancera by country 896 
(North America), 2005-09 897 
a Malignancies of the ovary (ICD-O-3 C56.9), fallopian tube, uterine ligaments and 898 
adnexa, and other and unspecified female genital organs (C57.0-C57.4, C57.7-899 
C57.9), and peritoneum and retroperitoneum (C48.0-C48.2). Endometrioid tumours 900 
are classified as type I epithelial (see text). *Data with 100% coverage of the national 901 
population. 902 
 903 
Supplementary Figure 4. Morphological groups of ovarian cancera by country 904 
(Europe), 2005-09 905 
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a Malignancies of the ovary (ICD-O-3 C56.9), fallopian tube, uterine ligaments and 906 
adnexa, and other and unspecified female genital organs (C57.0-C57.4, C57.7-907 
C57.9), and peritoneum and retroperitoneum (C48.0-C48.2). Endometrioid tumours 908 
are classified as type I epithelial (see text). *Data with 100% coverage of the national 909 
population. 910 
 911 
Supplementary Figure 5. Morphological groups of ovarian cancera by country 912 
(Oceania), 2005-09 913 
a Malignancies of the ovary (ICD-O-3 C56.9), fallopian tube, uterine ligaments and 914 
adnexa, and other and unspecified female genital organs (C57.0-C57.4, C57.7-915 
C57.9), and peritoneum and retroperitoneum (C48.0-C48.2). Endometrioid tumours 916 
are classified as type I epithelial (see text). *Data with 100% coverage of the national 917 
population. 918 
